CXCR4(S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4(S338X) clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4(S338X) clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Gustine, Joshua N., Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria Luisa, Chan, Gloria G., Patterson, Christopher J., Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784519/
https://ncbi.nlm.nih.gov/pubmed/31570491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000635
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados